Future studies will thus be necessary to further improve the therapeutic window of S2/IAPinh in combination with suitable partner dugs, a concept that has been recently successfully employed in the context of a PDX model in ovarian cancer, where the drug conjugate, SW IV-134 (a potent XIAP inhibitor with strong degradation capacity for cIAP1/2, see above), was used in combination with cisplatin, which led to a complete tumor eradication51. Here, XIAP is linked to ovarian cancer.